LENZ Therapeutics (LENZ) Interest Coverage Ratio (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Interest Coverage Ratio of 61.64 for Q1 2026, down 372.93% year-over-year from 22.58 in Q1 2025, and up 95.51% quarter-over-quarter from 1373.68 in Q4 2025.
LENZ Therapeutics (LENZ) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Interest Coverage Ratio for 7 consecutive years, with 61.64 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 372.93% year-over-year to 61.64; the TTM figure through Mar 2026 stood at 165.28 (down 261.13% YoY), while the FY2025 annual figure was 1.3, down 22.83% from the prior year.
- Interest Coverage Ratio rose to 61.64 in Q1 2026 per LENZ's latest filing, from 1373.68 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5.41 in Q4 2023 and bottomed at 1373.68 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 113.7 across 5 years, with a median of 8.56 in 2024.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio jumped 143.36% — and 2025, when it plunged 16095.42%.
- LENZ Therapeutics' Interest Coverage Ratio stood at 12.48 in 2022, then surged by 143.36% to 5.41 in 2023, then plunged by 256.71% to 8.48 in 2024, then slumped by 16095.42% to 1373.68 in 2025, then soared by 95.51% to 61.64 in 2026.
- Business Quant data shows LENZ's Interest Coverage Ratio at 61.64 in Q1 2026, 1373.68 in Q4 2025, and 18.35 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 1.42 |
| 10 | LENZ Therapeutics | 148.24 Mn | 148.24 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.39 |
| Mar 31, 2026 | -61.64 |
| Dec 31, 2025 | -1,373.68 |
| Sep 30, 2025 | -18.35 |
| Jun 30, 2025 | -14.71 |
| Mar 31, 2025 | -13.03 |
| Dec 31, 2024 | -8.48 |
| Sep 30, 2024 | -8.09 |
| Jun 30, 2024 | -8.56 |
| Mar 31, 2024 | -392.39 |
| Dec 31, 2023 | 5.41 |
| Sep 30, 2023 | -0.60 |
| Jun 30, 2023 | -0.43 |
| Mar 31, 2023 | -2.62 |
| Dec 31, 2022 | -12.48 |
| Sep 30, 2022 | -3.48 |
| Jun 30, 2022 | -0.04 |
| Mar 31, 2022 | -19.71 |
| Dec 31, 2021 | -9.45 |
| Sep 30, 2021 | -0.36 |